(Q37602845)

21 August 2017

1 reference

title

Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions (English)

1 reference

21 August 2017

Staphylococcus aureus

1 reference

1 reference

4

George Sakoulas

1 reference

21 August 2017

Pamela A Moise

1

1 reference

PubMed ID

19778764

21 August 2017

Donald North

series ordinal

2

1 reference

PubMed ID

19778764

21 August 2017

Judith N Steenbergen

series ordinal

3

1 reference

21 August 2017

1 October 2009

1 reference

Lancet Infectious Diseases

21 August 2017

1 reference

21 August 2017

9

1 reference

21 August 2017

10

1 reference

21 August 2017

617-624

1 reference

Historical yearly usage of vancomycin.

21 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Antimicrobial resistance: the example of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Microbiology of antibiotic resistance in Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Resistance studies with daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Functional relationship between bacterial cell density and the efficacy of antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

In vivo pharmacodynamic activity of daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Mutant selection window hypothesis updated.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Vancomycin resistance in gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970200-2

7 January 2021

10.1016/S1473-3099(09)70200-2

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19778764